NYSEAMERICAN:VNRX - VolitionRX Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.28 -0.10 (-2.96 %)
(As of 05/20/2019 04:00 PM ET)
Previous Close$3.38
Today's Range$3.23 - $3.41
52-Week Range$1.44 - $3.63
Volume21,700 shs
Average Volume91,239 shs
Market Capitalization$124.03 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Laboratories & Research
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:VNRX
Previous SymbolNYSEMKT:VNRX
CUSIPN/A
CIKN/A
Phone646 650 1351

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees44
Market Cap$124.03 million
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable

VolitionRX (NYSEAMERICAN:VNRX) Frequently Asked Questions

What is VolitionRX's stock symbol?

VolitionRX trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "VNRX."

How were VolitionRX's earnings last quarter?

VolitionRX Ltd (NYSEAMERICAN:VNRX) released its quarterly earnings results on Wednesday, May, 8th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). View VolitionRX's Earnings History.

When is VolitionRX's next earnings date?

VolitionRX is scheduled to release their next quarterly earnings announcement on Monday, August 12th 2019. View Earnings Estimates for VolitionRX.

What price target have analysts set for VNRX?

2 Wall Street analysts have issued 12-month target prices for VolitionRX's stock. Their forecasts range from $5.00 to $6.00. On average, they expect VolitionRX's stock price to reach $5.50 in the next year. This suggests a possible upside of 67.7% from the stock's current price. View Analyst Price Targets for VolitionRX.

What is the consensus analysts' recommendation for VolitionRX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VolitionRX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VolitionRX.

Has VolitionRX been receiving favorable news coverage?

News articles about VNRX stock have trended somewhat negative on Monday, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. VolitionRX earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.

Who are some of VolitionRX's key competitors?

What other stocks do shareholders of VolitionRX own?

Who are VolitionRX's key executives?

VolitionRX's management team includes the folowing people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 75)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 48)
  • Dr. Jacob Vincent Micallef Ph.D., MBA, Chief Scientific Officer (Age 63)
  • Dr. Jason Bradley Terrell, Chief Medical Officer (Age 39)
  • Mr. Rodney Gerard Rootsaert LLB, Corp. Sec. (Age 48)

Who are VolitionRX's major shareholders?

VolitionRX's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlueCrest Capital Management Ltd (0.07%), Charles Schwab Investment Management Inc. (0.04%), Renaissance Technologies LLC (0.03%) and Virtu Financial LLC (0.03%). Company insiders that own VolitionRX stock include Cameron John Reynolds, David Cecil Vanston and Guy Archibald Innes. View Institutional Ownership Trends for VolitionRX.

Which major investors are buying VolitionRX stock?

VNRX stock was bought by a variety of institutional investors in the last quarter, including BlueCrest Capital Management Ltd, Charles Schwab Investment Management Inc., Renaissance Technologies LLC and Virtu Financial LLC. Company insiders that have bought VolitionRX stock in the last two years include Cameron John Reynolds, David Cecil Vanston and Guy Archibald Innes. View Insider Buying and Selling for VolitionRX.

How do I buy shares of VolitionRX?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is VolitionRX's stock price today?

One share of VNRX stock can currently be purchased for approximately $3.28.

How big of a company is VolitionRX?

VolitionRX has a market capitalization of $124.03 million. VolitionRX employs 44 workers across the globe.

What is VolitionRX's official website?

The official website for VolitionRX is http://www.volitionrx.com/.

How can I contact VolitionRX?

The medical research company can be reached via phone at 646 650 1351.


MarketBeat Community Rating for VolitionRX (NYSEAMERICAN VNRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  285
MarketBeat's community ratings are surveys of what our community members think about VolitionRX and other stocks. Vote "Outperform" if you believe VNRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel